Education
About Us
Working with TipRanks
Follow Us
Merck & Company (MRK)
NYSE:MRK
MRK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$73.31 - $120.30
Previous CloseN/A
Volume3.30M
Average Volume (3M)14.76M
Market Cap
$199.10B
Enterprise Value$252.76B
Total Cash (Recent Filing)$9.23B
Total Debt (Recent Filing)$34.84B
Price to Earnings (P/E)12.2
Beta0.42
Next Earnings
Oct 30, 2025EPS Estimate
2.37Next Dividend Ex-Date
Sep 15, 2025Dividend Yield4.04%
Share Statistics
EPS (TTM)2.13
Shares Outstanding2,511,031,300
10 Day Avg. Volume13,728,685
30 Day Avg. Volume14,759,673
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue3.95
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda9.70
Forecast
1Y Price Target
$101.93Price Target Upside28.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering16
Bulls Say, Bears Say
Bulls Say
Cardiovascular SegmentMerck’s cardiovascular segment continues to outperform, with the PAH drug Winrevair showing significant sales growth.
Cost OptimizationThe newly announced $3bn optimization initiative is viewed as a sensible re-allocation of capital from slower growth areas to fund new launches and R&D.
Product DevelopmentPerformance from the company’s key new product cycle, Winrevair, remains intact and management reiterated optimism on tailwinds from a potential label expansion.
Bears Say
Gardasil Franchise UncertaintyPersisting uncertainty on the Gardisal franchise in both China and increasingly in the US due to lumpy CDC purchasing patterns and potential for lower dosing regimens.
Gardasil Sales DeclineMerck's Gardasil franchise continues to weigh on investor sentiment with back to back double-digit misses.
Vaccine Segment PerformanceVaccine revenue missed expectations, contributing to the negative sentiment.
Merck & Company News
MRK FAQ
What was Merck & Company’s price range in the past 12 months?
Merck & Company lowest stock price was $73.31 and its highest was $120.30 in the past 12 months.
What is Merck & Company’s market cap?
Merck & Company’s market cap is $199.10B.
When is Merck & Company’s upcoming earnings report date?
Merck & Company’s upcoming earnings report date is Oct 30, 2025 which is in 88 days.
How were Merck & Company’s earnings last quarter?
Merck & Company released its earnings results on Jul 30, 2025. The company reported $2.13 earnings per share for the quarter, beating the consensus estimate of $2.033 by $0.097.
Is Merck & Company overvalued?
According to Wall Street analysts Merck & Company’s price is currently Undervalued.
Does Merck & Company pay dividends?
Merck & Company pays a Quarterly dividend of $0.81 which represents an annual dividend yield of 4.04%. See more information on Merck & Company dividends here
What is Merck & Company’s EPS estimate?
Merck & Company’s EPS estimate is 2.37.
How many shares outstanding does Merck & Company have?
Merck & Company has 2,511,031,300 shares outstanding.
What happened to Merck & Company’s price movement after its last earnings report?
Merck & Company reported an EPS of $2.13 in its last earnings report, beating expectations of $2.033. Following the earnings report the stock price went down -1.065%.
Which hedge fund is a major shareholder of Merck & Company?
Currently, no hedge funds are holding shares in MRK
Merck & Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$101.93 (28.55% Upside)
$101.93 (28.55% Upside)
Blogger Sentiment
Bullish
MRK Sentiment 90%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 9.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days >0.1%
Last 30 Days ▲ 3.1%
Last 30 Days ▲ 3.1%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.98%
12-Months-Change
Fundamentals
Return on Equity
39.31%
Trailing 12-Months
Asset Growth
8.76%
Trailing 12-Months
Company Description
Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
MRK Company Deck
MRK Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
Merck's earnings call highlights steady performance in oncology and Animal Health, successful product launches, and a robust pipeline. However, significant declines in GARDASIL sales, particularly in China, and the impact of foreign exchange and tariffs present challenges.Read More>MRK Sales Breakdown
89.45% Pharmaceutical
9.16% Animal Health
1.39% Other
MRK Stock 12 Month Forecast
Average Price Target
$101.93
▲(28.55%Upside)
Technical Analysis
Ownership Overview
0.05% Insiders
20.82% Mutual Funds
1.26% Other Institutional Investors
52.63% Public Companies and Individual Investors